Merck Set To Add Perioperative Head-And-Neck Cancer To Keytruda Label

 
• By Joseph Haas
  
Merck presents successful data for Keytruda in perioperative head and neck cancer (Shutterstock)

More from Strategy

More from Therapy Areas